AG
CRSP icon

Algert Global’s CRISPR Therapeutics CRSP Stock Holding History

Algert Global’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.59M Sell
65,880
-30,940
-32% -$1.63M 0.04% 663
2026
Q1 		$4.61M Sell
96,820
-6,030
-6% -$318K 0.07% 463
2025
Q4 		$5.39M Buy
+102,850
New +$6.16M 0.08% 404
2024
Q4 		– Sell
-12,342
Closed -$580K – 1195
2024
Q3 		$580K Hold
12,342
– – 0.02% 875
2024
Q2 		$667K Buy
12,342
+3,832
+45% +$222K 0.02% 799
2024
Q1 		$580K Buy
+8,510
New +$609K 0.02% 743
2022
Q2 		– Sell
-16,943
Closed -$1.06M – 1231
2022
Q1 		$1.06M Buy
16,943
+9,420
+125% +$592K 0.07% 494
2021
Q4 		$570K Buy
7,523
+1,520
+25% +$133K 0.07% 485
2021
Q3 		$672K Buy
+6,003
New +$754K 0.09% 419

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Algert Global's CRSP Position: Q2 2026 in Review

Algert Global reduced its CRISPR Therapeutics (CRSP) stake by 32% in Q2 2026, selling an estimated $1.63M and leaving 65,880 shares worth $3.59M. The position accounts for 0.04% of the portfolio, ranked #663.

Algert Global first reported a position in CRSP in Q3 2021 and has held it in 9 quarters since. The position peaked at $5.39M in Q4 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Algert Global held 65,880 shares of CRISPR Therapeutics worth $3.59M as of Q2 2026.
  • Algert Global sold 30,940 CRISPR Therapeutics shares in Q2 2026, an estimated $1.63M.
  • CRISPR Therapeutics made up 0.04% of Algert Global's portfolio in Q2 2026, its #663 holding.
  • Algert Global first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • Algert Global's CRISPR Therapeutics position peaked at $5.39M in Q4 2025.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.